Nafamostat

Nafamostat

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate
CAS Number	81525-10-2 Y
PubChem CID	4413
IUPHAR/BPS	4262
ChemSpider	4260 N
UNII	Y25LQ0H97D
KEGG	D01670 N
Chemical and physical data
Formula	C19H17N5O2
Molar mass	347.37 g/mol
3D model (JSmol)	Interactive image
SMILES C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
InChI InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24) N Key:MQQNFDZXWVTQEH-UHFFFAOYSA-N N
NY (what is this?)

Nafamostat (INN), a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat is formulated with HCl salt due to its basic tendencies. This is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin.